CCCC C4 Therapeutics
- 4.080
- -0.060-1.45%
C4 Therapeutics News
Is C4 Therapeutics (NASDAQ:CCCC) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares sinc
It Looks Like C4 Therapeutics, Inc.'s (NASDAQ:CCCC) CEO May Expect Their Salary To Be Put Under The Microscope
C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors
Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership ExperienceBruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation
Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults
USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale...
We Think C4 Therapeutics (NASDAQ:CCCC) Can Afford To Drive Business Growth
Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), ACADIA Pharmaceuticals (ACAD) and Disc Medicine (IRON)
C4 Therapeutics Inc (CCCC) Q1 2024 Earnings: Navigating Challenges With Strategic Collaborations
On May 8, 2024, C4 Therapeutics Inc (NASDAQ:CCCC) released its 8-K filing, detailing the financial results for the first quarter ended March 31, 2024.
Express News | Wells Fargo Maintains Equal-Weight on C4 Therapeutics, Raises Price Target to $8
C4 Therapeutics Is Maintained at Buy by Stifel
C4 Therapeutics Is Maintained at Buy by Stifel
C4 Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 113.41% Stifel $13 → $14 Maintains Buy 02/26/2024 21.95% Morgan Stanley $1 → $8 Maintains Equal
Express News | C4 Therapeutics Inc : Stifel Raises Target Price to $14 From $13
C4 Therapeutics: Hold Rating Maintained Amidst Encouraging Drug Progress and Stable Financials
C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates
C4 Therapeutics (CCCC) shares were down 5% in recent Wednesday trading after the company reported its Q1 earnings. The company reported a Q1 diluted loss of $0.41 per share, narrowing from a per-share
Express News | C4 Therapeutics' Cash, Cash Equivalents and Marketable Securities Total $299.2M As Of March 31, 2024; Expected To Provide Runway Into 2027
Express News | C4 Therapeutics Q1 2024 GAAP EPS $(0.41) Beats $(0.47) Estimate, Sales $3.039M Miss $8.100M Estimate
C4 Therapeutics | 10-Q: Quarterly report
Express News | C4 Therapeutics Inc - Cash, Cash Equivalents and Marketable Securities Total $299.2 Mln as of March 31, 2024; Expected to Provide Runway Into 2027
C4 Therapeutics 1Q Loss $28.4M >CCCC
C4 Therapeutics 1Q Loss $28.4M >CCCC
Express News | C4 Therapeutics Q1 EPS USD -0.41 Vs. Ibes Estimate USD -0.35
Express News | C4 Therapeutics Q1 Revenue USD 3 Million Vs. Ibes Estimate USD 8.1 Million
Analysis
Price Target
No Data
